Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi, Dana E. Rathkopf, Matthew Raymond Smith et al. · Journal of Clinical Oncology · 2023
PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition. METHODS MAGNITUDE (ClinicalTrials.gov identifier: NCT03748641 ) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients with (HRR+, n = 423) or without (HRR−, n = 247) HRR-associated gene alterations, as prospectively determined by tissue/plasma-based assays. Patients were assigned 1:1 to receive niraparib + AAP or placebo + AAP. The primary end point, radiographic progression-free survival (rPFS) assessed by central review, was evaluated first in the BRCA1/2 subgroup and then in the full HRR+ cohort, with secondary end points analyzed for the full HRR+ cohort if rPFS was statistically significant. A futility analysis was preplanned in the HRR− cohort. RESULTS Median rPFS in the BRCA1/2 subgroup was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.6 v 10.9 months; hazard ratio [HR], 0.53; 95% CI, 0.36 to 0.79; P = .001). In the overall HRR+ cohort, rPFS was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.5 v 13.7 months; HR, 0.73; 95% CI, 0.56 to 0.96; P = .022). These findings were supported by improvement in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy. In the HRR− cohort, futility was declared per the prespecified criteria. Treatment with niraparib + AAP was tolerable, with anemia and hypertension as the most reported grade ≥ 3 adverse events. CONCLUSION Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP. [Media: see text]
Cited by 350 works. doi:10.1200/jco.22.01649
Authors
- Kim N. Chi
- Dana E. Rathkopf
- Matthew Raymond Smith
- Eleni Efstathiou
- Gerhardt Attard
- David Olmos
- Ji Youl Lee
- Eric Jay Small
- Andrea Juliana Gomes
- Guilhem Roubaud
- Marniza Bte Saad
- Bogdan A. Żurawski
- V.S. Sakalo
- Gary E. Mason
- Peter St. John Francis
- Brooke Diorio
- Angela Mennicke Lopez- Gitlitz
- Shahneen Kaur Sandhu
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- Integrative Clinical Genomics of Advanced Prostate Cancer
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer